Urotensin-II induces ear flushing in rats

British Journal of Pharmacology

Volumn 150, Issue 4, 2007, Pages 415-423

  Qi, J S ^a   Schulingkamp, R ^a,b   Parry, T J ^a   Colburn, R ^a   Stone, D ^a   Haertlein, B ^a   Minor, L K ^a   Andrade Gordon, P ^a   Damiano, B P ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Ear flush; Ear pinna surface temperature; Nitric oxide; Prostaglandin; Rat; Urotensin II; Vasodilation

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; INDOMETACIN; MECAMYLAMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROPRANOLOL; PROSTAGLANDIN; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN; UROTENSIN II;

ANIMAL EXPERIMENT; ARTICLE; CAPILLARY; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; EAR PINNA FLUSHING; EXTERNAL EAR DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN; TEMPERATURE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY TEMPERATURE; CALCITONIN GENE-RELATED PEPTIDE; EAR, EXTERNAL; ENZYME INHIBITORS; FLUSHING; INDOMETHACIN; INJECTIONS, SUBCUTANEOUS; MALE; MECAMYLAMINE; NG-NITROARGININE METHYL ESTER; NICOTINIC ANTAGONISTS; NITRIC OXIDE SYNTHASE TYPE III; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; UROTENSINS; VASODILATOR AGENTS;

EID: 33847109791     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707006     Document Type: Article

References (44)

1. Aloe L, Leon A, Levi-Montalcini R (1993). A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 39 (Spec No): C145-C147.
2. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM et al. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286.
3. Balment RJ, Song W, Ashton N (2005). Urotensin II: ancient hormone with new functions in vertebrate body fluid regulation. Ann NY Acad Sci 1040: 66-73.
4. Behm D, Doe C, Johns D, Maniscalco K, Stankus G, Wibberley A et al. (2004). Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn-Schmiedeberg's Arch Pharmacol 359: 271-273.
5. Belcheva A, Zhelyazkova M (1988). On the interaction between H1- and H2-histaminergic receptors in the histamine release and the realization of its vascular effects in the rat skin. Acta Phisol Pharmacol Bulg 14: 49-54.
6. Benrath J, Eschenfelder C, Zimmerman M, Gillardon F (1995). Calcitonin gene related peptide, substance P and nitric oxide are involved in cutaneous inflammation following ultraviolet irradiation. Eur J Pharmacol 293: 87-96.
7. Blacklock A, Cauveren J, Simth P (2004). Estrogen selectively increases sensory nociceptor innervation of arterioles in the female rat. Brain Res 1018: 55-65.
8. Borda E, Heizig G, Busch L, Sterin-Borda L (2002). Nitric oxide synthase/PGE(2) cross-talk in rat submandibular gland. Prostaglandins Leukot Essent Fatty Acids 67: 39-44.
9. Bottrill FE, Douglas SA, Hiley CR, White R (2000). Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130: 1865-1870.
10. Camarda V, Song W, Marzola E, Spagnol M, Guerrini R, Salvadori S et al. (2004). Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 498: 83-86.
11. Cheung BM, Leung R, Man YB, Wong LY (2004). Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22: 1341-1344.
12. Coulouarn Y, Jegou S, Tostivint H, Vaudry H, Lihrmann I (1999). Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 457: 28-32.
13. Di Girolamo G, Farina M, Riberio ML, Ogando D, Aisemberg J, de los Santos AR et al. (2003). Effects of cyclooxygenase inhibitor pretreatment on nitric oxide production, nNOS and iNOS expression in rat cerebellum. Br J Pharmacol 139: 1164-1170.
14. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A (2002). Congestive heart failure and expression of myocardial urotensin II. Lancet 359: 1990-1997.
15. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL et al. (2002). Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 136: 9-22.
16. Folkow B (1955). Nervous control of the blood pressure. Physiol Rev 35: 629-663.
17. Gardiner SM, March JE, Kemp PA, Bennett T (2004). Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response. Br J Pharmacol 143: 422-430.
18. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T (2001). Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132: 1625-1629.
19. Grant R (1963). Vasodilation and body warming in the rat. J Physiol 167: 311-317.
20. Gray GA, Jones MR, Sharif I (2001). Human urotensin II increases coronary perfusion pressure in the isolated rat heart. Potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 69: 175-180.
21. Hasegawa K, Kobayashi Y, Kobayashi H (1992). Vasodepressor effects of urotensin II in rats. Neuroendocrinol Lett 14: 357-363.
22. Hassan GS, Chouiali F, Saito T, Hu F, Douglas SA, Ao Z et al. (2003). Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol 81: 125-128.
23. Jegou S, Cartier D, Dubessy C, Gonzalez BJ, Chatenet D, Tostivint H et al. (2006). Localization of the urotensin II receptor in the rat central nervous system. J Comp Neurol 495: 21-36.
24. Katano Y, Ishihata A, Aita T, Ogaki T, Horie T (2000). Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 402: R5-R7.
25. Kiernan J (1976). Evidence for the involvement of vasoactive constituents of mast cells in axon reflex vasodilation in the skin of the rats. Acta Hepatogastroenterol (Stuttg) 255: 1-8.
26. Kiernan JA (1972). The involvement of mast cells in vasodilatation due to axon reflexes in injured skin. Q J Exp Physiol Cogn Med Sci 57: 311-317.
27. Kinney WA, Almond Jr HR, Qi J, Smith CE, Santulli RJ, de Garavilla L et al. (2002). Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl 41: 2940-2944.
28. Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD, Krum H (2004). Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 25: 1783-1788.
29. Langham RG, Kelly DJ, Gow RM, Zhang Y, Dowling JK, Thomson NM et al. (2004). Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44: 826-831.
30. Lin Y, Tsuchihashi T, Matsumura K, Abe I, Iida M (2003). Central cardiovascular action of urotensin II in conscious rats. J Hypertens 21: 159-165.
31. Madrigal JL, Garcia-Bueno B, Moro MA, Lizasoain I, Lorenzo P, Leza JC (2003). Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress. Eur J Neurosci 18: 1701-1705.
32. Maguire JJ, Kuc RE, Davenport AP (2000). Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131: 441-446.
33. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N et al. (2001). Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19: 2185-2190.
34. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE (2002). Plasma urotensin in human systolic heart failure. Circulation 106: 2877-2880.
35. Patacchini R, Santicioli P, Giuliani S, Grieco P, Novellino E, Rovero P et al. (2003). Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 140: 1155-1158.
36. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P et al. (2003). Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285: H1576-H1581.
37. Song W, Abdel AEL, Lu W, Ao Z, Johns DG, Douglas SA et al. (2006). Urotensin II and renal function in the rat. Kidney Int 69: 1360-1368.
38. Sugo T, Murakami Y, Shimomura Y, Harada M, Abe M, Ishibashi Y et al. (2003). Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310: 860-868.
39. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S et al. (2001). Role of urotensin II in patients on dialysis. Lancet 358: 810-811.
40. Turenne SD, Seeman M, Ross BM (2001). An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. Schizophr Res 50: 191-197.
41. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F et al. (2003). Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93: 246-253.
42. Wang YX, Pang CC (1991). Possible dependence of pressor and heart rate effects of NG-nitro-L-arginine on autonomic nerve activity. Br J Pharmacol 103: 2004-2008.
43. Watson AM, Lambert GW, Smith KJ, May CN (2003). Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42: 373-379.
44. Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P et al. (2003). Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 285: F792-F798.